The deadline to comment on FDA's generative AI paper is Oct 19, 2026. We explain why professionals in pharma manufacturing should weigh in.
|Articles|June 5, 2023
The Life Science Marketer's Checklist
Author(s)The Bracken Group
A robust marketing strategy is key to building brand equity and an effective, efficient sales pipeline—the overall goal. And the best way to develop that all-important strategy is to take stock of where you’re at and assess your resources. To aid in this self-assessment, we’ve developed The Life Science Marketer’s Checklist of must-haves for marketing professionals in the industry. This tool is designed to help you see your areas of strength and pinpoint areas you may have overlooked or have room for improvement.
Related to this article
The FDA expanded Anktiva to BCG-unresponsive papillary-only NMIBC using existing CIS trial data, a precedent with implications for development timelines and supply planning.
AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
Ishani Maharaj of Ingredients + Specialties from Univar Solutions explains how to stabilize GLP-1 multi-agonists, weigh delivery formats, and qualify novel excipients and suppliers.
MASH and cardiomyopathy AI collaboration: AstraZeneca pays insitro $40M upfront for target discovery, then leads clinical development and CMC planning.
Boyang Wang, Immortal Dragons, discusses how the FDA’s Expedited IND Pilot must prove efficiency as sponsors chase the fastest route to valid first-in-human data.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
The FDA’s Rare Disease Framework Initiative brings risk-based CMC review and pre-approval inspections into scope for sponsors, CDMOs, and quality teams.
Trending on Pharmaceutical Technology
1
Formulation Strategies for Next-Generation Multiagonists
2
NVIDIA’s $250M Agentic AI Safety Bet: What GMP Gains
3
Manufacturing Intelligence: What FDA's Real-World Use Case Database Means for CMC
4
First-in-Human Trial Speed: Why FDA Trails China
5